Synthetic glabridin derivatives mitigate steatohepatitis in a diet-induced biopsy-confirmed non-alcoholic steatosis hepatitis mouse model through paraoxonase-2
Authors:
Preprint
Abstract
Limited therapeutic agents have been developed for non-alcoholic steatohepatitis (NASH), a common immunometabolic disease that can progress to hepatic cirrhosis and cancer. Glabridin and its derivatives are potential therapeutics for some metabolic diseases. However, the therapeutic effects of glabridin and its derivatives on NASH and their biological functions are unclear. This study demonstrated the role of synthetic glabridin derivatives (SGDs) in alleviating hepatic steatosis and inflammation in a biopsy-confirmed rodent NASH model. SGDs exerted therapeutic effects by activating autophagy and the antioxidant defense system, which mitigate NASH pathogenesis. The cellular target of HSG4112, an SGD, was paraoxonase 2. These findings will enable the development of novel therapeutics for NASH in the future.Keywords
This publication has 52 references indexed in Scilit:
- Hypoglycemic effects of glabridin, a polyphenolic flavonoid from licorice, in an animal model of diabetes mellitusMolecular Medicine Reports, 2013
- The Phospholipid Profile of MycoplasmasJournal of Lipids, 2012
- Obesity-Dependent Metabolic Signatures Associated with Nonalcoholic Fatty Liver Disease ProgressionJournal of Proteome Research, 2012
- Mechanisms of lysophosphatidylcholine-induced hepatocyte lipoapoptosisAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2012
- Paraoxonase 2 Deficiency Alters Mitochondrial Function and Exacerbates the Development of AtherosclerosisAntioxidants & Redox Signaling, 2011
- Macroautophagy and Chaperone-Mediated Autophagy Are Required for Hepatocyte Resistance to Oxidant StressHepatology, 2010
- Autophagy regulates lipid metabolismNature, 2009
- The paraoxonases: role in human diseases and methodological difficulties in measurementCritical Reviews in Clinical Laboratory Sciences, 2009
- Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in MiceDiabetes, 2007
- Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiesJournal of Lipid Research, 2005